Aki Yoshida

3.9k citations
115 papers · 3.0k indexed · h-index 33
Topics
Sarcoma Diagnosis and Treatment (21 papers)Osteoarthritis Treatment and Mechanisms (18 papers)RNA Interference and Gene Delivery (12 papers)
Journals
SHILAP Revista de lepidopterologíaPLoS ONECancer

In The Last Decade

Aki Yoshida

110 papers receiving 2.9k citations

Peers

Aki Yoshida
Comparison fields: 5 of 135
  • Molecular Biology 1.3k
  • Rheumatology 657
  • Pulmonary and Respiratory Medicine 561
  • Oncology 552
  • Cancer Research 525
Replace Zhaoming Ye with:
Zhaoming Ye China
Aina He China
Anthony M. Reginato United States
Nikolaos G. Nikitakis United States
Min Tao China
Surapol Issaragrisil Thailand
Marie‐Françoise Heymann France
Akihiko Takeuchi Japan
Jianliu Wang China
Régis Brion France
Aki Yoshida relative to Zhaoming Ye China Zhaoming Ye's profile →
Citations per field
00.5×1.5×
Zhaoming Ye · 1×
Citations per year

Countries citing papers authored by Aki Yoshida

Since Specialization
Citations

This map shows the geographic impact of Aki Yoshida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aki Yoshida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aki Yoshida more than expected).

Fields of papers citing papers by Aki Yoshida

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aki Yoshida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aki Yoshida. The network helps show where Aki Yoshida may publish in the future.

Co-authorship network of co-authors of Aki Yoshida

This figure shows the co-authorship network connecting the top 25 collaborators of Aki Yoshida. A scholar is included among the top collaborators of Aki Yoshida based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aki Yoshida. Aki Yoshida is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 1
2 0
3 2
4 3
5 2
6 4
7 157
8 5
9 1
10 36
11 13
12 1
13 6
14 9
15 10
16 1
17 23
18 53
19 43
20 51

About Aki Yoshida

Aki Yoshida is a scholar working on Toxicology, Rheumatology and Health Informatics, having authored 115 papers that have together received 3.0k indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (21 papers), Osteoarthritis Treatment and Mechanisms (18 papers) and RNA Interference and Gene Delivery (12 papers). The work is most often cited by research in Rheumatology (657 citations), Cancer Research (525 citations) and Oncology (552 citations). Aki Yoshida has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Toshifumi Ozaki, Keiichiro Nishida, Toshiyuki Kunisada, Takayuki Furumatsu, Hajime Inoue, Yuki Morimoto, Akira Kawai, Takamitsu Komiyama, Mamoru Ouchida and Tomohiro Fujiwara. Their work appears in journals such as SHILAP Revista de lepidopterología, PLoS ONE and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026